EBMT China’s Voice | Professor Deyan Liu’s Team: Allogeneic Hematopoietic Stem Cell Transplantation Significantly Improves Survival Rates for Patients with Therapy-Related Myeloid Neoplasms
Therapy-related myeloid neoplasms (t-MN) are a distinct type of myeloid tumor that occur after cytotoxic or radiation therapy. In the 2022 WHO classification of hematopoietic and lymphoid tissue tumors, these were termed secondary myeloid neoplasms, including those related to cytotoxic treatment and genetic susceptibility. Compared to newly diagnosed AML, therapy-related AML (t-AML) has a poorer prognosis, including poor chemotherapy response, low rates of remission, and overall lower survival rates. From April 14-17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT 2024) held its annual meeting in Glasgow, UK. Dr. Yan Shu from the team of Professor Deyan Liu at Hebei Yanda Lu Daopei Hospital presented a clinical study (abstract number 391) that demonstrated allogeneic hematopoietic stem cell transplantation significantly improved survival rates in patients with t-MN.